3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
2
Immunoglobulin Light-chain Amyloidosis
2
Amyloidosis
2
Paraproteinemias
1
Monoclonal Gammopathy of Undetermined Significance
1
Interventions
Dexamethasone
7
Lenalidomide
5
isatuximab
3
fludarabine
3
daratumumab
3
Cyclophosphamide
3
Bortezomib
3
pomalidomide
2
Tacrolimus
2
Alemtuzumab
2
plerixafor
1
ofatumumab
1
nirogacestat
1
fludarabine phosphate
1
Whole-Body Irradiation
1
Tissue Banks
1
Thalidomide
1
Stem Cell Transplantation
1
Rifaximin
1
Ranitidine
1
Mycophenolic Acid
1
Melphalan
1
Granulocyte Colony-Stimulating Factor
1
Etoposide
1
Doxorubicin
1
Diphenhydramine
1
Clonal Hematopoiesis
1
Cisplatin
1
Chromatin Immunoprecipitation Sequencing
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Paraproteinemias
×
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
×
Clear all
NCT07624760
2026-06-03
MGUS-PET
University of Zurich
Phase NA
Not yet recruiting
50 enrolled